Revance Therapeutics (NASDAQ:RVNC) just reported results for the first quarter of 2024.
- Revance Therapeutics reported earnings per share of -54 cents. This was above the analyst estimate for EPS of -75 cents.
- The company reported revenue of $51.94 million.
- This was 8.29% worse than the analyst estimate for revenue of $56.63 million.